The First and Only FDA-Approved Technology for the Enhanced Detection of Bladder Cancer.
Bladder Cancer affects over a half million patients in the US and >80,000 new cases are expected per year. It is the #4 cancer in men and is observed in men 3-4 times more than women. Treatment is difficult since bladder tumors look similar to normal, healthy tissue. Due to this challenge, bladder cancer can be easily missed or incompletely removed and it has the highest rate of recurrence of all cancers according to the National Institutes of Health (NIH). Blue Light Cystoscopy with Cysview utilizes Photodynamic Diagnosis (PDD) to highlight cancerous bladder tumors in a bright pink color during surgery. It offers the following advantages over standard white light cystoscopy:
The 2-part PDD system consists of Blue Light Flexible Cystoscopy for on-going surveillance while the patient is awake, and Blue Light Rigid Cystoscopy for fluorescence guided resection with the UH400 Surgical generator.
The value of KARL STORZ Blue Light Cystoscopy with Cysview® 2 Part System comes from treating more bladder cancer patients more effectively. It can attract new patients and retain current ones by offering a better standard of care, which has been proven through excellent real-world outcomes, a strong recommendation by the AUA/SUO, and increased adoption and patient volume at top medical centers.
Blue Light Cystoscopy |view more
Thomas Cangiano, MD, Board-certified Urologist at Advent Health Altamonte Springs, FL, describes his initial experiences and observations when using the BLCC approach on his patients.
At 28 years old, Mary Beth Ballard received a bladder cancer diagnosis that would change her life. After getting the news and seeking multiple opinions, doctors at Vanderbilt University Medical Center were able to optimizing KARL STORZ ...
KARL STORZ Blue Light Cystoscopy with Cysview® System Value Analysis Brief
Blue Light Cystoscopy with Cysview® Financing Programs
DETECTION Equipment Overview Blue Light Flexible Cystoscopy with Cysview®
Approved Reprocessing Methods for Blue Light Cystoscopy
Value Analysis Brief KARL STORZ Blue Light Cystoscopy with Cysview® (BLCC) System
KARL STORZ Blue Light Cystoscopy with Cysview® System Brochure
Video showing ARC technology and comparing true bipolar to monopolar and semi-bipolar.
Videos |view more
Overview of kidney stone removal
Reach Stones Others Can’t. The ONLY Digital Ureteroscope to Reach Stones in Acute Angled Calicies.
This instructional video has been prepared by Julio Davalos,MD, of Chesapeake Urology Associates, who is also affiliated with theUniversity of Maryland.
This video compares a portion of an anastomosis procedure performed using standard microscopy techniques with the same procedure completed using the VITOM® System that allows visualization of the surgical field on a high-definition (HD) video monitor.
Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.
Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.
Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed.
Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition.
Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components.
Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.
Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.
Today’s diagnostic and therapeutic urologic procedures have been advanced by the development of modern endoscopic methods. Working elements for the operation of laser probes, rigid and flexible instruments for intervention in the ureter or for conservative nephrolithotomy, as well as instrument sets for laparoscopy and pediatric urology have expanded the range of essential endourological products developed by KARL STORZ. Among the new and emerging technologies recently developed are Photodynamic diagnosis (PDD) for early recognition of non-muscle-invasive bladder cancer, Bipolar HF resection, Laser cystoscopy, Improved PCNL procedures.